Open AccessEvaluation of glutathione S‐transferase pi 1 expression and gene promoter methylation in Moroccan patients with urothelial bladder cancer
Author(s) -
Hadami Khaoula,
Dakka Nadia,
Bensaid Mounia,
El Ahanidi Hajar,
Ameur Ahmed,
Chahdi Hafsa,
Oukabli Mohamed,
Al Bouzidi Abderrahmane,
Attaleb Mohammed,
El Mzibri Mohammed
Publication year - 2018
Publication title -
molecular genetics and genomic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.765
H-Index - 29
ISSN - 2324-9269
DOI - 10.1002/mgg3.449
Subject(s) - methylation , bladder cancer , cancer research , gene , glutathione s transferase , gene expression , cancer , biology , glutathione , medicine , microbiology and biotechnology , genetics , enzyme , biochemistry
Abstract Background Glutathione S‐transferase pi 1 ( GSTP 1) is a cytosolic detoxifying enzyme that protects cells against deleterious effects of oxidative stress. Deregulated expression of GSTP 1 protein and aberrant promoter methylation of GSTP 1 gene were reported in various human tumors and were shown to be involved in the molecular pathway for cancer development. Aims and methods In this study, we aimed to determine the expression status of GSTP 1 in relation to its gene promoter methylation in Moroccan population of 30 bladder cancer ( BC ) patients and in two noncancerous bladder tissues used as controls. GSTP 1 expression was assessed by immunohistochemistry and GSTP 1 gene promoter methylation status was studied by methylation‐specific PCR ( MS ‐ PCR ). Results Glutathione S‐transferase pi 1 was expressed in the two normal tissues. In BC cases, GSTP 1 expression was strong in 23.33% (7/30), moderate in 60% (18/30), and weak in 13.33% (4/30) of cases, while GSTP 1 was not expressed in one cancer case (3.33%). Variability of GSTP 1 expression does not correlate with high‐grade cancer or invasive‐stage ( p > 0.05). No GSTP 1 gene promoter methylation was detected in all control and cancer cases. Conclusion Our data suggest that GSTP 1 expression is not associated with BC development, limiting its use as a biomarker for BC management in Morocco. Moreover, difference in GSTP 1 expression among BC cases is not due to GSTP 1 promoter methylation.